These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34894110)

  • 41. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
    Christensen MC; Florea I; Lindsten A; Baldwin DS
    J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder.
    Gonda X; Sharma SR; Tarazi FI
    Expert Opin Drug Discov; 2019 Jan; 14(1):81-89. PubMed ID: 30457395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
    Christensen MC; Munro V
    Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vortioxetine: A new alternative for the treatment of major depressive disorder.
    Salagre E; Grande I; Solé B; Sanchez-Moreno J; Vieta E
    Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(1):48-59. PubMed ID: 28800937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
    Mahableshwarkar AR; Affinito J; Reines EH; Xu J; Nomikos G; Jacobsen PL
    CNS Spectr; 2020 Jun; 25(3):352-362. PubMed ID: 31199210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
    Christensen MC; Sluth LB; McIntyre RS
    J Affect Disord; 2019 Feb; 245():508-516. PubMed ID: 30439678
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.
    Levada OA; Troyan AS; Pinchuk IY
    BMC Psychiatry; 2020 May; 20(1):208. PubMed ID: 32384884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial.
    Cao B; Park C; Rosenblat JD; Chen Y; Iacobucci M; Subramaniapillai M; Mansur RB; Zuckerman H; Lee Y; McIntyre RS
    J Psychopharmacol; 2019 Nov; 33(11):1388-1394. PubMed ID: 31530216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment.
    Basurte-Villamor I; Vega P; Roncero C; Martínez-Raga J; Grau-López L; Aguilar L; Torrens M; Szerman N
    Neuropsychiatr Dis Treat; 2022; 18():965-976. PubMed ID: 35547266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Motivation and Energy Inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study.
    Christensen MC; Adair M; Loft H; McIntyre RS
    J Affect Disord; 2023 Feb; 323():547-553. PubMed ID: 36395989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial.
    Manna CK; Ranjan R; Kumar P; Ahmad S; Nath S
    Indian J Psychiatry; 2023 Aug; 65(8):815-824. PubMed ID: 37736222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute dosing of vortioxetine strengthens event-related brain activity associated with engagement of attention and cognitive functioning in rats.
    Laursen B; Bundgaard CH; Graversen C; Grupe M; Sanchez C; Leiser SC; Sorensen HBD; Drewes AM; Bastlund JF
    Brain Res; 2017 Jun; 1664():37-47. PubMed ID: 28366617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 57. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.
    Jacobsen P; Zhong W; Nomikos G; Clayton A
    J Sex Med; 2019 Oct; 16(10):1638-1649. PubMed ID: 31405765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder.
    Sumiyoshi T; Hoshino T; Mishiro I; Hammer-Helmich L; Ge H; Moriguchi Y; Fujikawa K; Fernandez JL
    J Affect Disord; 2022 Jan; 296():95-102. PubMed ID: 34597893
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial.
    Borhannejad F; Shariati B; Naderi S; Shalbafan M; Mortezaei A; Sahebolzamani E; Saeb A; Hosein Mortazavi S; Kamalzadeh L; Aqamolaei A; Ali Noorbala A; Namazi-Shabestari A; Akhondzadeh S
    J Clin Pharm Ther; 2020 Aug; 45(4):804-811. PubMed ID: 32420649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.